To Explore the Factors Affecting the Effectiveness of Smoking Cessation

Status Completed

Clinical Trial Summary

Objectives:

Promoting quitting smoking and training smoking cessation educators in hospital, school, community, and workplace was being vigorously pushed by Health Promotion Administration. Since the implementation of the second-generation smoking cessation program by Health Promotion Administration, both the general public and medical institutions have worked with greater vitality to practice and promote quitting smoking. However, studies on smoking cessation in the inpatient remain inadequate. Increasing cessation motivation for inpatient smokers and evaluating their nicotine dependence are essential. In this study, we aimed to explore the factors that might influence the smoking cessation in the inpatients.

Method: A cross-sectional questionnaire survey was conducted on inpatients participants at the smoking cessation.

Questionnaire comprising（1）Demographic characteristics: age, sex, marital status, education, （2）physiological factors（concentration of carbon monoxide, nicotine dependence, disease severity）,（3）psychological factors（psychological dependence on smoking , smoking cessation stages of behavior change, smoking cessation self-efficacy）, （4）Social Factor: social support,（5）smoking Behavior indicators: smoked, daily cigarette consumption, smoking experience. After giving health education cessation of treatment one month, three months and six months, interviewed by telephone quitting behavior index contains daily cigarette consumption, quit rates point.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Smoking Cessation

Clinical Trial Details

NCT number	NCT03474783
Study type	Interventional
Source	Cathay General Hospital
Contact
Status	Completed
Phase	N/A
Start date	September 22, 2015
Completion date	February 2, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT03999411` - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients	Phase 4
Completed	`NCT04617444` - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function	N/A
Completed	`NCT02796391` - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes	Phase 2
Completed	`NCT03397511` - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City	N/A
Not yet recruiting	`NCT05188287` - A Culturally Tailored Smartphone Application for African American Smokers	N/A
Recruiting	`NCT05264428` - The Effect of Honey on Lessening the Withdrawal Symptoms	N/A
Completed	`NCT04133064` - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study	N/A
Completed	`NCT03187730` - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants	Phase 4
Completed	`NCT04635358` - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center	N/A
Terminated	`NCT03670264` - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation	N/A
Completed	`NCT02997657` - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial	N/A
Completed	`NCT03206619` - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed	`NCT02905656` - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit	N/A
Completed	`NCT02239770` - Pharmacokinetics of Nicotine Film in Smokers	N/A
Completed	`NCT02562521` - A Smoking Cessation Intervention for Yale Dining Employees	Phase 4
Recruiting	`NCT02422914` - Benefits of Tobacco Free Cigarette	N/A
Enrolling by invitation	`NCT02218944` - Smoking Response Inhibition Training	N/A
Completed	`NCT03002883` - STAND Community College Tobacco Cessation Trial	N/A
Completed	`NCT02230384` - Novel Smoking Cessation Drug for Schizophrenia	Phase 2